Search results for "Factor V"

showing 10 items of 146 documents

Factor VII deficiency: evidence that in minor surgery one-day replacement therapy is sufficient

2011

Inherited FACTOR VII DEFICIENCY MINOR SURGERY INVASIVE PROCEDURESSettore MED/15 - Malattie Del Sangue
researchProduct

Oral Communication

2012

Inherited factor VII (FVII) deficiency is the most common of the rare autosomal recessive bleeding disorders (RBD), with an estimated prevalence of 1 per 300,000 in European countries.1,2 It is likely that the prevalence is higher in those countries where consanguineous marriages are frequent.We here report STER study results on 112 evaluable enrolled cases

Inherited Factor VII deficiency prophylaxisspontaneous bleeding episodesSettore MED/15 - Malattie Del Sangue
researchProduct

Recombinant activated factor VII administration in a patient with congenital lack of factor VII undergoing laparoscopic hysterectomy: A case report

2021

Highlights • Patients with lack of factor VIIa, suffering from abnormal uterine bleedings can be treated with laparoscopic hysterectomy. • Technique using bipolar coagulation and non-absorbable clips is safe and not time consuming. • Pre-operative loading with recombinant factor VIIa must be followed by prolonged supplementation in post-operative period. • We present suggested dosage and length of factor VIIa supplementation based on literature review and own experience.

Laparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentHysterectomySurgical bleeding03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCase reportmedicineotorhinolaryngologic diseasesCLIPSLaparoscopycomputer.programming_languageHysterectomyFactor VIImedicine.diagnostic_testbiologybusiness.industrymedicine.diseaseEndometrial hyperplasiaSurgerychemistryRecombinant factor VIIa030220 oncology & carcinogenesisFactor VII deficiencybiology.protein030211 gastroenterology & hepatologySurgeryPremedicationLaparoscopysense organsbusinesscomputercirculatory and respiratory physiologyInternational Journal of Surgery Case Reports
researchProduct

Clinical aspects of bleeding complications in cirrhotic patients

2000

Liver disease is a frequent cause of haemostatic abnormalities, which may lead to overt or occult bleeding. Clinical manifestations of hepatic coagulopathy include upper and lower gastrointestinal haemorrhage, easy bruising and bleeding from gums, nose or the female genital tract. The most significant bleeding problem among patients with chronic liver disease is blood loss due to portal hypertension. About 30% of subjects with oesophageal or gastric varices resulting from cirrhosis have an episode of gastrointestinal bleeding in their lifetime. Risk factors for the first episode of variceal bleeding include the severity of liver dysfunction, large varices, and the presence of endoscopic red…

Liver CirrhosisMaleGastrointestinal bleedingmedicine.medical_specialtyCirrhosisBiopsyDysfunctional uterine bleedingHemorrhageFactor VIIaChronic liver diseasePostoperative ComplicationsmedicineHumansFirst episodebusiness.industryBacterial InfectionsHematologyGeneral MedicineGastric varicesmedicine.diseaseRecombinant ProteinsSurgeryPortal hypertensionFemalemedicine.symptombusinessVaricesBlood Coagulation & Fibrinolysis
researchProduct

Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms

2005

Abstract Background. Prothrombin time is a benchmark for functional assessment in cirrhosis and Factor VII levels (FVII), crucial in determining the prothrombin time, are genetically determined. Methods. We have evaluated the prothrombin time, a number of haemostatic variables synthesised by the liver (FII, FV, FVII and activated FVII, AT and fibrinogen) and two polymorphisms of the FVII gene (5′F7 and 353R/Q) in: (a) patients with liver cirrhosis ( n  = 118), (b) patients with chronic hepatitis ( n  = 102) and (c) controls ( n  = 100). Results. By one-way analyses of variance, the prothrombin time and the mean levels of the FII, FV, FVIIc, FVIIa, and AT were statistically different between…

Liver Cirrhosismedicine.medical_specialtyCirrhosisGenotypeLiver CirrhosiFibrinogenChronic liver diseasechemistry.chemical_compoundhemic and lymphatic diseasesInternal medicineGenotypemedicineHumansAlleleAllele frequencyAllelesHepatitis ChronicProthrombin timeAllelePolymorphism GeneticHepatologyFactor VIImedicine.diagnostic_testbusiness.industryGastroenterologyFactor VIImedicine.diseaseEndocrinologychemistryCase-Control StudiesProthrombin TimebusinessCase-Control Studiemedicine.drugHuman
researchProduct

Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER

2011

MAJOR SURGERY FACTOR VII DEFICIENCY
researchProduct

Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction.

2011

Thrombotic risk increases in elderly, therefore, the understanding of the genetic predisposition of hypercoagulability could make the difference in the prevention of venous and/or arterial thrombotic events. Laboratory evaluation of hyperfibrinogenemia, increased Factor VII levels, antiphospholipid antibodies presence and hyperhomocysteinemia are considered to have a consistent high predictivity for arterial thrombophilic diseases. Anyway, a large debate exists on the validity of testing Leiden Factor V (FV) G1691A and/or prothrombin (FII) G20210A polymorphisms in patients affected by arterial thrombotic diseases, despite of the several observations described. Here we report data strongly s…

MaleAgingmedicine.medical_specialtyHyperhomocysteinemiaLeiden Factor V; Prothrombin; Stroke; Guidelines; Arterial thrombosis.Myocardial InfarctionHyperfibrinogenemiaGuidelineGUIDELINESGastroenterologyCohort Studieschemistry.chemical_compoundInternal medicineArterial DisorderGenotypeGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAgedAged 80 and overPolymorphism GeneticFactor VIIbusiness.industryFactor VMiddle Agedmedicine.diseaseSurgeryStrokeTHROMBOSISchemistryArterial thrombosis.Prothrombin G20210AFemaleProthrombinGeriatrics and GerontologybusinessGerontologyLeiden Factor V
researchProduct

Prothrombotic gene variants as risk factors of acute myocardial infarction in young women

2012

Abstract Background Acute myocardial infarction (AMI) in young women represent an extreme phenotype associated with a higher mortality compared with similarly aged men. Prothrombotic gene variants could play a role as risk factors for AMI at young age. Methods We studied Factor V Leiden, FII G20210A, MTHFR C677T and beta-fibrinogen -455G>A variants by real-time PCR in 955 young AMI (362 females) and in 698 AMI (245 females) patients. The data were compared to those obtained in 909 unrelated subjects (458 females) from the general population of the same geographical area (southern Italy). Results In young AMI females, the allelic frequency of either FV Leiden and of FII G20210A was signif…

MaleHomocysteineMyocardial Infarctionlcsh:Medicinegene variantsprothrombotic gene variantsAMIchemistry.chemical_compoundGene FrequencyRisk FactorsgenderMyocardial infarctionMedicine(all)GeneticsYoung AMI Gender AMI Gene variants Mutations Prothrombotic variants Genetic predispositioneducation.field_of_studyprothrombotic variantsbiologyHomozygoteFactor VGeneral MedicineFemaleProthrombinyoung AMIAdultmedicine.medical_specialtyPopulationyoung AMI gender AMI gene variants mutations prothrombotic variants genetic predisposition.Polymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyInternal medicinemedicineFactor V LeidenGenetic predispositionHumansGenetic Predisposition to Diseasecardiovascular diseaseseducationAllele frequencyAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchlcsh:RFactor VThrombosismutationsmedicine.diseasechemistryMethylenetetrahydrofolate reductasebiology.proteinbusinessgenetic predispositionJournal of Translational Medicine
researchProduct

Portal Vein Thrombosis in a Preterm Newborn with Mutation of the MTHFR and PAI-1 Genes and Sepsis by Candida parapsilosis

2016

Objective This report discusses the role of both congenital and acquired risk factors in the pathogenesis of portal vein thrombosis (PVT). Study Design We describe the clinical management and treatment of PVT in a preterm newborn with a homozygous mutation of the methylenetetrahydrofolate reductase (MTHFR) and plasminogen activator inhibitor-1 (PAI-1) genes and sepsis by Candida parapsilosis. Results Although literature data suggest a minor role of genetic factors in thrombophilia in the case of only one mutation, we hypothesize that combined thrombophilic genetic defects may have a cumulative effect and significantly increase the thrombotic risk. Conclusion It could be appropriate to incl…

MalePathologymedicine.medical_specialtyCandida parapsilosis030204 cardiovascular system & hematologyBioinformaticsCandida parapsilosisThrombophiliaSepsisPathogenesis03 medical and health sciences0302 clinical medicineSepsis030225 pediatricsPlasminogen Activator Inhibitor 1medicineHumansMethylenetetrahydrofolate Reductase (NADPH2)Venous ThrombosisPolymorphism GeneticbiologyPortal Veinbusiness.industryCandidiasisInfant NewbornAnticoagulantsFactor VObstetrics and Gynecologyportal thrombosis fungal infection gene polymorphismmedicine.diseasebiology.organism_classificationPortal vein thrombosisSurgical Procedures OperativeMethylenetetrahydrofolate reductaseMutationPediatrics Perinatology and Child Healthbiology.proteinGene polymorphismbusinessPlasminogen activatorAmerican Journal of Perinatology
researchProduct

Expression of p53 Protein and Tumor Angiogenesis as Prognostic Factors in Nasopharyngeal Carcinoma Patients.

2002

The objective of this study was to evaluate the possible prognostic significance of p53 protein overexpression and tumor angiogenesis (TA) in nasopharyngeal carcinoma (NPC) patients, together with other clinicopathological variables. Forty-two NPC patients were evaluated in relation to survival. Nuclear p53 overexpression in neoplastic and endothelial cells was detected by immunohistochemistry (IHC) with the monoclonal antibody DO-7 and the polyclonal antibody against factor VIII-related antigen, respectively. Thereafter, we evaluated p53 cases in order to determine their nuclear immunoreactivity from negative (-) to positive (+, ++, +++). In addition, microvessels were counted in the most …

MalePathologymedicine.medical_specialtymedicine.drug_classBiologyMonoclonal antibodyPathology and Forensic MedicineNeovascularizationImmunoenzyme TechniquesAntigenmedicineBiomarkers TumorHumansCàncerMicrovesselSurvival analysisProportional Hazards ModelsRetrospective StudiesFactor VIIINeovascularization PathologicMicrocirculationCarcinomaNas MalaltiesCancerNasopharyngeal NeoplasmsCell BiologyMiddle Agedmedicine.diseasePrognosisPatologiaSurvival RateNasopharyngeal carcinomaCancer researchCarcinoma Squamous CellImmunohistochemistryFemalemedicine.symptomTumor Suppressor Protein p53
researchProduct